Alphamab Oncology of Suzhou has started a Phase I clinical trial of its humanized PD-L1/CTLA-4 bispecific antibody in Australia. The company has also been approved to conduct a similar China trial of the candidate, KN046. The company said KN046 is engineered to target the tumor microenvironment, reducing side effects, while its dual target mechanism increases efficacy. In preclinical studies, KN046 showed excellent anti-tumor activity, according to Alphamab, with less toxicity than the marketed CTLA-4 antibody Yervoy. Alphamab said the Australian clinical trial also demonstrated good tolerability in humans.
Source: China Biotoday
